Global Adrenocortical Carcinoma Treatment Market, By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Drug Type (Tamoxifen, Mifepristone, Toremifene, Spironolactone, Others), Treatment (Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, Biologic Therapy, Others), Diagnosis (MRI, CT Scan, PET Scan, Biopsy, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Global Adrenocortical Carcinoma Treatment Market
Adrenocortical carcinoma treatment market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6% in the above mentioned forecast period.
Adrenocortical carcinoma is defined as a rare disease which is caused due to the growth of cancer cells in the adrenal cortex. Adrenal cortex is the outer layer of adrenal gland which is responsible for the production of hormones that are involved in the regulation of blood pressure and metabolism. It is also involved in the production of cortisol and androgens. The excessive production of these hormones is occurred due to adrenocortical carcinoma. This condition is characterised by the symptoms such as increased facial and body hair mainly in females, excessive weight gain, high blood pressure, abdominal pain, muscle weakness, bruising in the body and enlargement of breast tissue in the males.
Rise in the prevalence of rare cancers, growing healthcare expenditure, increasing focus of companies on the treatment of adrenocortical carcinoma, advancement in imaging technologies for the identification of adrenocortical tumor, surge in the number of cancer treatment centers, growing government funding and rising initiatives by government and private organisations to spread awareness about the cancer are the factors that will expand the adrenocortical carcinoma treatment market.
Rise in the research and development activities and ongoing clinical trials will provide beneficial opportunities for the adrenocortical carcinoma treatment market in the forecast period of 2021-2028.
However, high cost of treatment and high risk associated with the local recurrence and metastatic progression are the factors that will hinder the market growth and will further challenge the adrenocortical carcinoma treatment market in the forecast period mentioned above.
This adrenocortical carcinoma treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adrenocortical carcinoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Adrenocortical Carcinoma Treatment Market Scope and Market Size
The adrenocortical carcinoma treatment market is segmented on the basis of type, drug type, treatment, diagnosis, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the adrenocortical carcinoma treatment market is segmented into localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.
- On the basis of drug type, the adrenocortical carcinoma treatment market is segmented into tamoxifen, mifepristone, toremifene, spironolactone and others.
- On the basis of treatment, the adrenocortical carcinoma treatment market is segmented into surgery, chemotherapy, targeted therapy, radiation therapy, biologic therapy and others.
- On the basis of diagnosis, the adrenocortical carcinoma treatment market is segmented into MRI, CT scan, PET scan, biopsy and others.
- On the basis of end-users, the adrenocortical carcinoma treatment market is segmented into clinic, hospital and others.
The adrenocortical carcinoma treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Adrenocortical Carcinoma Treatment Market Country Level Analysis
Adrenocortical carcinoma treatment market is analyzed and market size information is provided by the country, type, drug type, treatment, diagnosis, end-users and distribution channel as referenced above.
The countries covered in the adrenocortical carcinoma treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the adrenocortical carcinoma treatment market due to the presence of major key players, growing incidences of adrenocortical carcinoma, high disposable income, and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing healthcare expenditure, rising awareness about the treatment and diagnostic methods of disease, favourable reimbursement scenario and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Adrenocortical carcinoma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Adrenocortical Carcinoma Treatment Market Share Analysis
Adrenocortical carcinoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to adrenocortical carcinoma treatment market research.
The major players covered in the adrenocortical carcinoma treatment market report are HRA Pharma, GENERAL ELECTRIC COMPANY, WG Critical Care, LLC, Bristol-Myers Squibb Company, Mylan N.V., Pfizer Inc., Fresenius Kabi AG, SinoVision, Hitachi, Ltd., NeuroLogica Corp., DIGIRAD CORPORATION, Merck Sharp & Dohme Corp., EnGeneIC Ltd., Exelixis, Inc., Tempest Therapeutics, Inc., ORPHAGEN PHARMACEUTICALS, Integra LifeSciences, and Zimmer Biomet among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-